Cargando…

Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data

PURPOSE: Erectile dysfunction (ED) is associated with testosterone deficiency and is a symptom of functional hypogonadism. A correlation between ED and cardiovascular disease (CVD) has been recognized, and ED has been proposed as an early marker of CVD. However, the relationship between ED and CVD r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alwani, Mustafa, Yassin, Aksam, Talib, Raidh, Al-Qudimat, Ahmad, Aboumarzouk, Omar, Al-Zoubi, Raed M, Saad, Farid, Haider, Karim S, Al Ansari, Abdulla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403087/ https://www.ncbi.nlm.nih.gov/pubmed/34465997 http://dx.doi.org/10.2147/VHRM.S309714

Ejemplares similares

The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study
por: Alwani, Mustafa, et al.
Publicado: (2021)

Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study
por: Al-Qudimat, Ahmad, et al.
Publicado: (2021)

Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size
por: Yassin, Aksam, et al.
Publicado: (2023)

A systematic review on the latest developments in testosterone therapy: Innovations, advances, and paradigm shifts
por: Al-Zoubi, Raed M., et al.
Publicado: (2021)

Testosterone and Covid‐19: An update
por: Yassin, Aksam, et al.
Publicado: (2022)

Sex‐based differences in severity and mortality in COVID‐19
por: Alwani, Mustafa, et al.
Publicado: (2021)

Psychosocial impact of COVID-19 pandemic: experience of healthcare workers in Qatar
por: Al-Qudimat, Ahmad R., et al.
Publicado: (2023)

Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes
por: Haider, Ahmad, et al.
Publicado: (2014)

Is there a relationship between the severity of erectile dysfunction and the comorbidity profile in men with late onset hypogonadism?
por: Yassin, Aksam A., et al.
Publicado: (2015)

Erectile Dysfunction in Qatar: Prevalence and Risk Factors in 1,052 Participants—A Pilot Study
por: Al Naimi, Abdulla, et al.
Publicado: (2014)

Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
por: Al‐Qudimat, Ahmad R., et al.
Publicado: (2022)

Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men
por: Saad, Farid, et al.
Publicado: (2015)

Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism
por: Almehmadi, Yousef, et al.
Publicado: (2016)

Testosterone depot injection in male hypogonadism: a critical appraisal
por: Yassin, Aksam A, et al.
Publicado: (2007)

COVID‐19 effect on patients with noncommunicable diseases: A narrative review
por: Al‐Qudimat, Ahmad R., et al.
Publicado: (2022)

Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope
por: Al-Omari, Mothana K., et al.
Publicado: (2023)

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study
por: Haider, Ahmad, et al.
Publicado: (2016)

Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy
por: Haider, Ahmad, et al.
Publicado: (2017)

Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options
por: Saad, Farid, et al.
Publicado: (2011)

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report
por: Haider, Ahmad, et al.
Publicado: (2019)

Diagnostic Inflammation Biomarkers for Prediction of 30-Day Mortality Rate in Acute Cholangitis
por: Al-Yahri, Omer, et al.
Publicado: (2022)

Lower urinary-tract symptoms and testosterone in elderly men
por: Yassin, Aksam A., et al.
Publicado: (2008)

The Effect of Testosterone Replacement Therapy on Penile Hemodynamics in Hypogonadal Men With Erectile Dysfunction, Having Veno-Occlusive Dysfunction
por: Efesoy, Ozan, et al.
Publicado: (2018)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

Salvage minimally invasive robotic and laparoscopic pyeloplasty in adults: a systematic review
por: Elaarag, Mai, et al.
Publicado: (2022)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Saad, Farid, et al.
Publicado: (2019)

The Association of Hypertension with Increased Mortality Rate During the COVID-19 Pandemic: An Update with Meta-analysis
por: Al-Qudimat, Ahmad R., et al.
Publicado: (2023)

OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

The triad of erectile dysfunction, hypogonadism and the metabolic syndrome
por: Shabsigh, R, et al.
Publicado: (2008)

Hypogonadism and erectile dysfunction as harbingers of systemic disease
por: Chiles, Kelly A.
Publicado: (2016)

Low-intensity extracorporeal shockwave therapy for erectile dysfunction
por: Canguven, Onder, et al.
Publicado: (2021)

Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms
por: Saad, Farid, et al.
Publicado: (2018)

Understanding the cellular basis and pathophysiology of Peyronie’s disease to optimize treatment for erectile dysfunction
por: Campbell, Jeffrey, et al.
Publicado: (2017)

Hypogonadism and erectile dysfunction in myotonic dystrophy type 1
por: PERIC, STOJAN, et al.
Publicado: (2013)

New treatment possibilities for postcovid hypogonadism and erectile dysfunction
por: Knigavko, Prof. Oleksandr V., et al.
Publicado: (2022)

New treatment possibilities for postcovid hypogonadism and erectile dysfunction.
por: Knigavko, Oleksandr V., et al.
Publicado: (2022)

Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies
por: Saad, F, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ov6ei8p6k59vrgrn5bdtbd0nrg